Protocol Number: 99-C-0125
Patients =25 years old and diagnosed with osteosarcoma may be eligible for this study. Candidates are screened with a medical history and physical examination, blood and urine tests, MUGA (nuclear medicine test of heart function) or echocardiogram, computed tomography (CT) magnetic resonance imaging (MRI), bone scans, chest x-ray and , a hearing test. Participants have a catheter (plastic tube) placed in a vein through which they receive treatment with chemotherapy, other medicines, intravenous fluids, and blood, if needed. Blood samples can be withdrawn through the catheter. Chemotherapy consists of doxorubicin, cisplatin and methotrexate given over 9 weeks. In addition, patients receive a drug called dexrazoxane before each dose of doxorubicin to protect the heart from possible injury due to doxorubicin, and they receive leucovorin after methotrexate to protect healthy cells from potential side effects of that drug. When first screened and after 9 weeks of chemotherapy, patients have a type of MRI called dynamic enhanced magnetic resonance imaging (DEMRI). In addition to showing the bone and muscle, DEMRI provides information on blood flow in the area affected by the tumor. MRI takes about 35 minutes to complete, and the DEMRI portion of the imaging may take an additional 15 to 60 minutes. DEMRI may be done in conjunction with or separately from conventional MRI. After the first 10 weeks of chemotherapy, patients are referred for surgery to remove the primary tumor and any other tumor tissue that may have spread to other sites. Portions of the tumor may be used for research tests. The removed tumor is examined to determine the amount of tumor that has survived, and patients then receive more courses of doxorubicin with dexrazoxane, cisplatin and methotrexate.
Search The Studies | Help | Questions |
National Institutes of Health Clinical Center |
||